Drug Trial Radar · NCT06834295
A Study to Evaluate Metabolism, Excretion, and Mass Balance of [14C]Vapendavir
Last checked: Nov 19, 2026Latest source record: May 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Mar 12, 2025
Primary completion
Mar 23, 2025
Study completion Mar 23, 2025
Sponsor
- Lead sponsor
- Altesa Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 30 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess how the body processes, breaks down and removes a new test medicine (vapendavir) from the body in healthy male participants.The main question it aims to answer is how the body handles the test medicine. In order to do that, the test medicine will be radiolabeled to track the test medicine in the body. Healthy male participants who meet entry criteria will be admitted to the clinic for a duration of approximately 9 days (Day -1 to Day 8). Participants will be admitted in the evening on the day before dosing (Day -1). Participants will take a single oral dose of radiolabeled vapendavir on Day 1 and have samples collected and safety tests completed during various times throughout their stay in the the clinic. The safety tests will provide additional information on the safety and tolerability of the test medicine.
Conditions
- Healthy Males
Interventions
VapendavirDrug
Single oral dose of \[14C\]vapendavir
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the mass balance recovery after a single oral dose of carbon-14 ([14C])vapendavir.Time frame: From enrollment until the mass balance criteria have been met (~ 8 days).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quotient Sciences
Nottingham, UK, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.